260 related articles for article (PubMed ID: 34350953)
1. Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease.
McCarthy GM; Blasio A; Donovan OG; Schaller LB; Bock-Hughes A; Magraner JM; Suh JH; Tattersfield CF; Stillman IE; Shah SS; Zsengeller ZK; Subramanian B; Friedman DJ; Pollak MR
Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34350953
[TBL] [Abstract][Full Text] [Related]
2. APOL1-G0 protects podocytes in a mouse model of HIV-associated nephropathy.
Bruggeman LA; Wu Z; Luo L; Madhavan S; Drawz PE; Thomas DB; Barisoni L; O'Toole JF; Sedor JR
PLoS One; 2019; 14(10):e0224408. PubMed ID: 31661509
[TBL] [Abstract][Full Text] [Related]
3. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis.
Ge M; Molina J; Ducasa GM; Mallela SK; Varona Santos J; Mitrofanova A; Kim JJ; Liu X; Sloan A; Mendez AJ; Banerjee S; Liu S; Szeto HH; Shin MK; Hoek M; Kopp JB; Fontanesi F; Merscher S; Fornoni A
Hum Mol Genet; 2021 Apr; 30(3-4):182-197. PubMed ID: 33517446
[TBL] [Abstract][Full Text] [Related]
4. Re-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression.
Hawkins GA; Friedman DJ; Lu L; McWilliams DR; Chou JW; Sajuthi S; Divers J; Parekh RS; Li M; Genovese G; Pollack MR; Hicks PJ; Bowden DW; Ma L; Freedman BI; Langefeld CD
Am J Nephrol; 2015; 42(2):99-106. PubMed ID: 26343748
[TBL] [Abstract][Full Text] [Related]
5. APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice.
Ryu JH; Ge M; Merscher S; Rosenberg AZ; Desante M; Roshanravan H; Okamoto K; Shin MK; Hoek M; Fornoni A; Kopp JB
PLoS One; 2019; 14(4):e0211559. PubMed ID: 30998685
[TBL] [Abstract][Full Text] [Related]
6. Inaxaplin for Proteinuric Kidney Disease in Persons with Two
Egbuna O; Zimmerman B; Manos G; Fortier A; Chirieac MC; Dakin LA; Friedman DJ; Bramham K; Campbell K; Knebelmann B; Barisoni L; Falk RJ; Gipson DS; Lipkowitz MS; Ojo A; Bunnage ME; Pollak MR; Altshuler D; Chertow GM;
N Engl J Med; 2023 Mar; 388(11):969-979. PubMed ID: 36920755
[TBL] [Abstract][Full Text] [Related]
7.
Zhang JY; Wang M; Tian L; Genovese G; Yan P; Wilson JG; Thadhani R; Mottl AK; Appel GB; Bick AG; Sampson MG; Alper SL; Friedman DJ; Pollak MR
Proc Natl Acad Sci U S A; 2018 Mar; 115(13):3446-3451. PubMed ID: 29531077
[TBL] [Abstract][Full Text] [Related]
8. An Acidic Environment Induces APOL1-Associated Mitochondrial Fragmentation.
Li D; Snipes JA; Murea M; Molina AJA; Divers J; Freedman BI; Ma L; Petrovic S
Am J Nephrol; 2020; 51(9):695-704. PubMed ID: 32866949
[TBL] [Abstract][Full Text] [Related]
9. DGAT2 Inhibition Potentiates Lipid Droplet Formation To Reduce Cytotoxicity in APOL1 Kidney Risk Variants.
Chun J; Riella CV; Chung H; Shah SS; Wang M; Magraner JM; Ribas GT; Ribas HT; Zhang JY; Alper SL; Friedman DJ; Pollak MR
J Am Soc Nephrol; 2022 May; 33(5):889-907. PubMed ID: 35232775
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein L1 High-Risk Genotypes and Albuminuria in Sub-Saharan African Populations.
Brandenburg JT; Govender MA; Winkler CA; Boua PR; Agongo G; Fabian J; Ramsay M
Clin J Am Soc Nephrol; 2022 Jun; 17(6):798-808. PubMed ID: 35577564
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic mice.
Aghajan M; Booten SL; Althage M; Hart CE; Ericsson A; Maxvall I; Ochaba J; Menschik-Lundin A; Hartleib J; Kuntz S; Gattis D; Ahlström C; Watt AT; Engelhardt JA; Monia BP; Magnone MC; Guo S
JCI Insight; 2019 Jun; 4(12):. PubMed ID: 31217349
[TBL] [Abstract][Full Text] [Related]
12. Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease.
Gupta Y; Friedman DJ; McNulty MT; Khan A; Lane B; Wang C; Ke J; Jin G; Wooden B; Knob AL; Lim TY; Appel GB; Huggins K; Liu L; Mitrotti A; Stangl MC; Bomback A; Westland R; Bodria M; Marasa M; Shang N; Cohen DJ; Crew RJ; Morello W; Canetta P; Radhakrishnan J; Martino J; Liu Q; Chung WK; Espinoza A; Luo Y; Wei WQ; Feng Q; Weng C; Fang Y; Kullo IJ; Naderian M; Limdi N; Irvin MR; Tiwari H; Mohan S; Rao M; Dube GK; Chaudhary NS; Gutiérrez OM; Judd SE; Cushman M; Lange LA; Lange EM; Bivona DL; Verbitsky M; Winkler CA; Kopp JB; Santoriello D; Batal I; Pinheiro SVB; Oliveira EA; Simoes E Silva AC; Pisani I; Fiaccadori E; Lin F; Gesualdo L; Amoroso A; Ghiggeri GM; D'Agati VD; Magistroni R; Kenny EE; Loos RJF; Montini G; Hildebrandt F; Paul DS; Petrovski S; Goldstein DB; Kretzler M; Gbadegesin R; Gharavi AG; Kiryluk K; Sampson MG; Pollak MR; Sanna-Cherchi S
Nat Commun; 2023 Nov; 14(1):7836. PubMed ID: 38036523
[TBL] [Abstract][Full Text] [Related]
13. Sequencing rare and common APOL1 coding variants to determine kidney disease risk.
Limou S; Nelson GW; Lecordier L; An P; O'hUigin CS; David VA; Binns-Roemer EA; Guiblet WM; Oleksyk TK; Pays E; Kopp JB; Winkler CA
Kidney Int; 2015 Oct; 88(4):754-63. PubMed ID: 25993319
[TBL] [Abstract][Full Text] [Related]
14. APOL1 polymorphisms and kidney disease: loss-of-function or gain-of-function?
Bruggeman LA; O'Toole JF; Sedor JR
Am J Physiol Renal Physiol; 2019 Jan; 316(1):F1-F8. PubMed ID: 30332315
[TBL] [Abstract][Full Text] [Related]
15. APOL1 Kidney Risk Variants Induce Cell Death
Shah SS; Lannon H; Dias L; Zhang JY; Alper SL; Pollak MR; Friedman DJ
J Am Soc Nephrol; 2019 Dec; 30(12):2355-2368. PubMed ID: 31558683
[TBL] [Abstract][Full Text] [Related]
16. APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease.
Bruggeman LA; Wu Z; Luo L; Madhavan SM; Konieczkowski M; Drawz PE; Thomas DB; Barisoni L; Sedor JR; O'Toole JF
J Am Soc Nephrol; 2016 Dec; 27(12):3600-3610. PubMed ID: 27026370
[TBL] [Abstract][Full Text] [Related]
17. Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity.
Chun J; Zhang JY; Wilkins MS; Subramanian B; Riella C; Magraner JM; Alper SL; Friedman DJ; Pollak MR
Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3712-3721. PubMed ID: 30733285
[TBL] [Abstract][Full Text] [Related]
18. APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress.
Wen H; Kumar V; Lan X; Shoshtari SSM; Eng JM; Zhou X; Wang F; Wang H; Skorecki K; Xing G; Wu G; Luo H; Malhotra A; Singhal PC
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29967295
[TBL] [Abstract][Full Text] [Related]
19. Kidney Disease-Associated
Datta S; Kataria R; Zhang JY; Moore S; Petitpas K; Mohamed A; Zahler N; Pollak MR; Olabisi OA
J Am Soc Nephrol; 2020 Sep; 31(9):2083-2096. PubMed ID: 32675303
[TBL] [Abstract][Full Text] [Related]
20. APOL1 risk variants and the development of HIV-associated nephropathy.
Goyal R; Singhal PC
FEBS J; 2021 Oct; 288(19):5586-5597. PubMed ID: 33340240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
